PatientsVille.com Logo

WEIGHT INCREASED and Lithium

PatientsVille

WEIGHT INCREASED Symptoms and Causes

Do you know if your current weight is healthy? "Underweight", "normal", "overweight", and "obese" are all labels for ranges of weight. Obese and overweight mean that your weight is greater than it should be for your health. Underweight means that it is lower than it should be for your health. Your healthy body weight depends on your sex and height. For children, it also depends on your age.

A sudden, unexpected change in weight can be a sign of a medical problem. Causes for sudden weight loss can include

  • Thyroid problems
  • Cancer
  • Infectious diseases
  • Digestive diseases
  • Certain medicines

Sudden weight gain can be due to medicines, thyroid problems, heart failure, and kidney disease.

Good nutrition and exercise can help in losing weight. Eating extra calories within a well-balanced diet and treating any underlying medical problems can help to add weight.

Check out the latest treatments for WEIGHT INCREASED

WEIGHT INCREASED treatment research studies

Lithium clinical trials, surveys and public health registries


Find Drug Side Effect reports



Lithium Side Effects

Therapeutic Agent Toxicity (237)
Confusional State (205)
Tremor (179)
Toxicity To Various Agents (167)
Renal Failure Acute (132)
Dehydration (107)
Diarrhoea (106)
Nausea (96)
Nephrogenic Diabetes Insipidus (93)
Blood Creatinine Increased (91)
Dysarthria (87)
Agitation (83)
Mania (80)
Mental Status Changes (78)
Hyperparathyroidism (77)
Asthenia (77)
Dizziness (77)
Fall (72)
Renal Failure Chronic (71)
Vomiting (68)
Insomnia (66)
Disorientation (66)
Fatigue (61)
Gait Disturbance (61)
Bradycardia (61)
Depression (60)
Haemodialysis (57)
Completed Suicide (56)
Suicide Attempt (56)
Anxiety (56)
Somnolence (53)
Depressed Level Of Consciousness (53)
Overdose (52)
Renal Failure (51)
Hypercalcaemia (51)
Delirium (51)
Hypernatraemia (50)
Neuroleptic Malignant Syndrome (49)
Renal Cyst (49)
Hypotension (47)
Nephropathy (46)
Hypothyroidism (45)
Lethargy (45)
Condition Aggravated (45)
Ataxia (44)
Renal Impairment (43)
Coma (41)
Abnormal Behaviour (40)
Dyspnoea (40)
Weight Increased (39)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

Abdominal distention with lithium and seroquel. 20-30 yr. use

Developed bruxism after starting abilify and lithium

Lithium causes depression by way of suppression by way of a mental block it creates in ones mind . this leads to suicidal thoughts then thinking of killing oneself. if you are misdiagnosed bi polar and you are not this will probably happen. if there

Makes my bp much better but am very bloated and llegs hurt. hard to walk

Weight gain of 25 lbs. Normally weigh 120. Os tjos possible

<b><span style='font-weight: normal;'><b>After 6 weeks of oral lamisil I experienced</b>eczema, muscle weakness, asthma, bloody bowels, lower abdominal pain, dizziness, extreme f

I have been put on Molipaxin 3 weeks ago, I have dry mouth, hair loss and my panic attacks were showing no signs of improvement. Dr increased it to 100mg and put me onto Lamictin. I am not bi polar nor epileptic. My disorder ist algora phoebia. I a

I have just come back from a funeral for my brother. He was just 62. He was on statin medicine but his cholestrol, blood pressure, weight and diet was very much in control. In fact just a day before his death the doctor told him that he was doing f

Side effects I have from Nadolol are confusion, dizziness, lightheaded, increased depression and anxiety, and mild nausea.

Has anyone gained weight from taking xyzal? It has helped my alergies but I've gained 12 lbs.....

Have taken hydrea for a year because my spleen had increased in size. I have noticed increased loss of memory and some confusion for the past couple of months. I take 500 mg every other day and 1000 mg every other day.

I don't know. I have been taking Lithium for my Bi-Polar for three years now, and besides the weight gain, I have been doing well! My Doctor wants me to try Zeldox, what should I do?

I have experienced weight loss of a pound a month for the last 2 years, since taking 100 mcg per day. My dr. can find no cause for this loss. I also have taken Metformin for about the same amount of time.

On 4/25/2006, I took the first of the three Hepatitis B shots. I suddenly had flu like symptoms which lasted for ever. I started getting really weak. I would eventually start losing weight. I went from 269 down to 118. I was diagnosed with Dermatomy

WEIGHT INCREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Unknown  In Vivo Lithium Treatment Effects on Gene Expression Levels in Lymphoblastoid Cell Lines From Human Healthy Subjects
Condition: Drug Mechanism
Intervention: Drug: Lithium Carbonate
Outcome Measures: Expression levels of genes (known to be regulated by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment.;   Expression levels of a protein, BDNF (known to be regulated by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment.;   Enzymatic activity of Complex I (known to be altered by Lithium) analyzed in lymphoblastoid cell cultures established from lymphocytes sampled in healthy volunteers before and after one month of Lithium treatment.
2 Recruiting Neuroprotective Effects of Lithium in Patients With Small Cell Lung Cancer Undergoing Radiation Therapy to the Brain
Condition: Small Cell Lung Carcinoma
Intervention: Drug: Lithium Carbonate
Outcome Measures: Dose-limiting toxicities of Lithium (DLTs), (safety lead-in);   Rate of immediate recall memory deterioration at 3 months, (phase II);   Rate of immediate recall memory deterioration at 6 and 12 months;   Rate of delayed recall memory deterioration at 3, 6 and 12 months;   Incidence of brain metastases;   Overall survival;   Changes in quality-of-life following PCI;   Change in hippocampal morphology following Lithium + PCI;   Incidence of adverse events;   Feasibility of performing serial neurocognitive testing and quality of life exams in patients wit
3 Recruiting Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: tretinoin;   Drug: Lithium carbonate;   Other: laboratory biomarker analysis
Outcome Measure: Maximum tolerated dose of tretinoin when given together with Lithium carbonate, defined as the dose level immediately below that at which at least 2/6 subjects experience dose-limiting toxicity (DLT), graded using the NCI CTCAE version 4.0
4 Recruiting Gao Bipolar Spectrum Lithium/Quetiapine Study
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Quetiapine
Outcome Measures: Time to study discontinuation;   Lithium vs. Quetiapine effects on general cardiovascular disease risk and role effects on general cardiovascular disease risk and role impairment
5 Not yet recruiting Lithium for Suicidal Behavior in Mood Disorders
Conditions: Depressive Disorder;   Bipolar Disorder;   Suicide;   Suicide, Attempted
Interventions: Drug: Lithium;   Drug: Placebo
Outcome Measure: Time to the first repeated episode of suicidal self-directed violence, including suicide attempts, interrupted attempts and hospitalizations for prevention of attempts.
6 Recruiting Ketamine Plus Lithium in Treatment-Resistant Depression
Condition: Depression
Interventions: Drug: Ketamine and Lithium;   Drug: Ketamine and Placebo
Outcome Measures: Montgomery Asberg Depression Rating Scale;   Quick Inventory of Depressive Symptoms;   Patient Rated Inventory of Side Effects (PRISE);   Clinical Global Impression;   Hamilton Psychiatric Rating Scale for Anxiety (HAM-A)
7 Unknown  Lithium and Standard Therapy in Resistant Depression
Condition: Depression
Interventions: Drug: Lithium;   Drug: usual care
Outcome Measures: Suicide completion and acts of deliberate self harm (DSH) will constitute the composite primary outcome;   All-cause mortality;   Suicide mortality;   Deliberate self-harm or attempted suicide;   Change in severity of depressive symptoms from baseline;   Adverse reactions during the study
8 Recruiting The Neurotrophic Effects of Lithium Carbonate Following Stroke: A Feasibility Study
Condition: Stroke
Intervention: Drug: Lithium Carbonate
Outcome Measures: Increase in total brain gray matter volumes;   Cognitive tasks of the Neurological Disorders and Stroke - Canadian Stroke Network's (NINDS-CSN) 30 min. battery;   Serum brain-derived neurotrophic factor (BDNF) levels;   Serum Lithium and creatinine levels
9 Not yet recruiting Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode
Conditions: Suicidal Ideation/Behavior;   Depression
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
Outcome Measures: S-STS;   C-SSRS
10 Unknown  The Influence of the Menstrual Cycle on Lithium and Sertraline Blood Levels
Conditions: Bipolar Affective Disorders;   Cyclothymic Disorder;   Schizoaffective Disorder;   Major Depressive Disorder;   Dysthymic Disorder;   Obsessive-Compulsive Disorder;   Panic Disorder;   Posttraumatic Stress Disorder;   Premenstrual Dysphoric Disorder;   Social Anxiety Disorder
Intervention:
Outcome Measures: blood levels of Lithium or sertraline;   Fluctuations in symptom severity;   Correlations between Symptom Severity and Blood Levels of Drugs
11 Recruiting Potentiation of Quetiapine Treatment With Lithium or Aripiprazole in Bipolar 1 Nonresponders Patients
Condition: Bipolar I Disorder
Interventions: Drug: Lithium;   Drug: Aripiprazole
Outcome Measure: The main outcome will be the number of patients that achieve and remain in remission to each treatment at the end of each phase of the study
12 Not yet recruiting Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma
Condition: Osteosarcoma
Intervention: Drug: Lithium Carbonate
Outcome Measures: progression-free survival,incidence of chemotherapy-induced myelosuppression;   over-all survival,metastasis-free survival
13 Recruiting Lithium Augmentation for Hyperarousal Symptoms of Post Traumatic Stress Disorder: Pilot Study
Conditions: Combat Posttraumatic Stess Disorder;   Mild Traumatic Brain Injury
Intervention: Drug: Lithium Carbonate
Outcome Measures: Udvalg for Kliniske Undersogelser Side Effect Rating Scale;   Clinician Administered Posttraumatic Stress Disorder Scale;   Beck Scale for Suicide Ideation
14 Not yet recruiting Lithium Versus Paroxetine in Major Depression
Condition: Major Depressive Disorder
Interventions: Drug: Lithium;   Drug: Paroxetine
Outcome Measures: Montgomery Asberg Depression Rating Scale (MADRS);   The Young Mania Rating Scale (YMRS);   The Clinical Global Impression (CGI);   The Columbia Suicide Classification Scale;   Barnes Akathisia Rating Scale (BARS);   Treatment -emergent symptom checklist and questionnaire
15 Unknown  Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Conditions: Bipolar Disorder;   Schizoaffective Disorder
Interventions: Drug: Olanzapine;   Drug: Lithium;   Drug: Chlorpromazine
Outcome Measures: Safety;   ¨The frequency of treatment-emergent adverse events (events that first appear or worsen during the study period) will be compared between both groups.;   ¨The frequency of side effects as rated with the UKU scale will be compared between both groups.;   ¨Weight gain will be compared between both groups.;   ¨Frequency of changes in vital signs and laboratory findings will be compared between both groups.;   Subjective well being;   ¨Total scores on the DAI and the SWN will be compared between both groups.;   Adherence;   ¨Degree of adherence to the treatment as scored on the MARS will be compared between both groups.;   Efficacy;   ¨End point analysis: Mean change in various scales from baseline to week 4 and week 8 will be used to compare the efficacy of the two treatments:;   ¨Primary efficacy analysis will be assessed by comparing the mean change in theYMRS total score.;   ¨Secondary efficacy analysis will be assessed by comparing the mean change in CGI-BP total score and in BPRS total score.;   ¨Response analysis: Response is defined as at least a 50% drop in the total YMRS total score from base line to the 8-weeks end point. Euthymia is defined as a total score on the YMRS of no greater than 12 at end point. The number of patients reaching bot;   Incidence of depressive episodes;   ¨A worsening in the HAMD-21 score of at least 3 points will be used as a definition of a clinically detectable worsening in depressive symptoms.;   Six and 12 months outcome;   Definition of recovery:;   ¨Syndromic recovery: Eight contiguous weeks [50] during which the patient no longer meets criteria for a manic, mixed, or depressive syndrome. Recovery from each of these syndromes is based on DSM-IV criteria and is operationalised as follows: manic synd;   ¨Symptomatic recovery: Eight contiguous weeks [50] during which the patient experiences minimal to no psychiatric symptoms, operationalized as follows: Young Mania Rating Scale total score of 5 or less, Hamilton depression scale total score of 10 or les;   ¨Relapse: Relapse is defined as the return of symptoms after a remission of less than 8 weeks.;   ¨Recurrence: Recurrence is defined as return of symptoms after recovery.;   ¨Functional recovery: Return to premorbid levels of function for at least 8 contiguous weeks [50]. To assess functional recovery, seven of the nine general items from the Premorbid Adjustment Scale are evaluated at the 6 and 12-month follow-up visit for
16 Recruiting Comparative Efficacy and Acceptability of Antimanic Drugs in Acute Mania
Condition: Bipolar Disorder
Interventions: Drug: Lithium;   Drug: Valproate;   Drug: Oxcarbazepine;   Drug: Quetiapine;   Drug: Olanzapine;   Drug: Ziprasidone
Outcome Measures: Change from baseline in Young Mania Rating Scale at 2 weeks and 6 weeks;   rate of dropout (treatment discontinuation);   Clinical Global Impressions (CGI) Scale;   Brief Psychiatric Rating Scale;   Global Assessment Scale;   Treatment Emergent Symptom Scale;   Hamilton Anxiety Rating Scale;   Hamilton Depression Rating Scale
17 Recruiting A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung Cancer
Condition: Small Cell Lung Cancer
Intervention: Drug: Lithium
Outcome Measures: Feasibility of a project design where the patients are randomized into Lithium or placebo;   Neurocognition
18 Recruiting Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain
Conditions: Neuropathic Pain;   Neuralgia;   Spinal Cord Injuries
Interventions: Drug: Lithium Carbonate;   Drug: Placebo
Outcome Measures: Change from Baseline in Numeric Rating Scale (NRS) at 24 weeks;   Change in multidimensional pain inventory life interference subscale (MPI-LIS);   Change in Short-Form 36 single question;   Change in Sleep interference assessment score;   Change in Weekly number of days with pain attack;   Change in the Patient global impression of change (PGIC);   Change in PHQ-9;   Change in AISA sensory scores, motor scores and AISA impairment scale;   Change in Modified Ashworth Scale;   Magnetic resonance diffusion tensor imaging (optional);   Electrophysiology (optional)
19 Recruiting Multimodal Neuroimaging of Treatment Effects in Adolescent Mania
Conditions: Mania;   Bipolar Disorder
Interventions: Drug: Quetiapine & Placebo;   Drug: Lithium and Placebo;   Other: Healthy Controls
Outcome Measure: The purpose of this study is to use magnetic resonance imaging (MRI) to examine brain structure, function and chemistry in people with Bipolar I disorder (manic or mixed episodes) who are being treated with either quetiapine or Lithium.
20 Unknown  An Initial Study of Lithium in Patients With Medullary Thyroid Cancer
Condition: Medullary Thyroid Cancer
Intervention: Drug: Lithium carbonate
Outcome Measure: tumor response rate